Utilizing Gene Editing to Explore the Function of the MYC Gene in Chronic Myelogenous Leukemia and Human Non-Small Cell Lung Cancer

Chronic myelogenous leukemia (CML) and non-small cell lung cancer (NSCLC) are two common malignant tumors. Traditional treatments mainly include chemotherapy, radiotherapy, and bone marrow transplantation for CML. However, the low success rate of donor matching limits the widespread use of bone marrow transplants. The development of tumors is closely related to mutations or overexpression of multiple oncogenes, but their regulatory mechanisms and effective therapeutic strategies are still unclear. In recent years, the rapid development of gene editing technology, especially the CRISPR-Cas9 system, has provided new technical means for screening therapeutic targets for leukemia and lung cancer. This project utilizes the CRISPR-Cas9 system to knock out the MYC gene, which is considered a key oncogene in many human cancers. The first step of this project is to construct MYC gene knockout cell lines for CML and NSCLC, and to evaluate the effects on tumor cell proliferation and differentiation in vitro. It is expected that knocking out the MYC gene will significantly inhibit tumor cell proliferation and activate the expression of differentiation-related genes. This study will help reveal the role of the MYC gene in tumorigenesis and provide important theoretical support and potential clinical application value for targeted therapy of CML and NSCLC, further promoting the development of personalized precision medicine.